NCT02664805 is a Phase 2 clinical trial of LEO 124249 ointment in Chronic Hand Eczema, sponsored by LEO Pharma.

Who is sponsoring NCT02664805?

NCT02664805 is sponsored by LEO Pharma.

What drugs are being tested in NCT02664805?

Interventions in NCT02664805: LEO 124249 ointment, LEO 124249 ointment vehicle.

What condition does NCT02664805 study?

NCT02664805 studies Chronic Hand Eczema.

Is NCT02664805 still recruiting?

NCT02664805 is currently completed. Last updated 24 April 2026.

Last reviewed 2026-04-24 · How we verify

NCT02664805

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Completed Phase 2 Last updated 24 April 2026

What this trial tests

Phase 2 trial testing LEO 124249 ointment in Chronic Hand Eczema in 91 participants. Completed in 1 October 2016.

Timeline

1 February 2016

Primary endpoint
1 July 2016

1 October 2016

Quick facts

Lead sponsor	LEO Pharma
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	91
Start date	1 February 2016
Primary completion	1 July 2016
Estimated completion	1 October 2016
Sites	1 location across Germany

Drugs / interventions tested

LEO 124249 ointment — full drug profile →
LEO 124249 ointment vehicle — full drug profile →

Conditions studied

Chronic Hand Eczema — all drugs for Chronic Hand Eczema →

Sponsor

LEO Pharma — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Hand Eczema. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)
Time frame: 56 days
Treatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear

Sponsor's own description

To compare the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249 ointment vehicle for up to 8 weeks in the treatment of subjects with chronic hand eczema.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F, Meier K, Ghoreschi K. · · 2019 · cited 199× · PMID 31849996 · DOI 10.3389/fimmu.2019.02847
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al · · 2024 · cited 95× · PMID 37923366 · DOI 10.1136/ard-2023-223850
Interventions for hand eczema.
Christoffers WA, Coenraads PJ, Svensson Å, Diepgen TL, et al · · 2019 · cited 37× · PMID 31025714 · DOI 10.1002/14651858.cd004055.pub2
Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges.
Dubin C, Del Duca E, Guttman-Yassky E. · · 2020 · cited 33× · PMID 33408476 · DOI 10.2147/tcrm.s292504

Verify or expand the search:

Other recruiting trials for Chronic Hand Eczema

Currently open trials in the same condition.

NCT05026554 — Characterization of Chronic Hand Eczema · recruiting

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02664805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 24 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02664805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing